Novel compounds act as 5-HT2C agonists to treat psychotic disorders, implying potential new therapies.
Provided herein are novel mixed serotonin receptor binder compounds as 5-HT2C agonists, pharmaceutical compositions, use of such compounds in treating psychotic disorders, and processes for preparing such compounds.
No takes yet. Share an insight, caveat, or question.
Ram W. Sabnis (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: